The results showed that the mRNA expression levels of AHCY (0.0064±0.00067 vs 0.0074±0.00076 vs 0.0121±0.00137, P = 0.003), ACO2 (0.20±0.014 vs 0.20±0.034 vs 0.56±0.087, P<0.001), OXCT1 (0.0043±0.00037 vs 0.0036±0.00029 vs 0.0059±0.00054, P = 0.039) and CAP1 (0.094±0.0095 vs 0.059±0.0052 vs 0.135±0.0109, P = 0.004) were significantly reduced in both HD patients and preHD carriers when compared with the controls by ANCOVA with adjustment of age and gender (Table 2). The gene discussed is AHCY; the disease is Huntington disease.